Ciprofloxacin and probiotic Escherichia coli Nissle add-on treatment in active ulcerative colitis: A double-blind randomized placebo controlled clinical trial

Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The probiotic bacterium Escherichia coli Nissle 1917 (EcN) has been used to maintain and induce clinical remission in UC. Our aim was to test the effect of Ciprofloxacin and/or orally administered EcN as add-on to conventional therapie...

Full description

Saved in:
Bibliographic Details
Published in:Journal of Crohn's and colitis 2014-11, Vol.8 (11), p.1498-1505
Main Authors: Petersen, Andreas Munk, Mirsepasi, Hengameh, Halkjær, Sofie Ingdam, Mortensen, Esben Munk, Nordgaard-Lassen, Inge, Krogfelt, Karen Angeliki
Format: Article
Language:English
Subjects:
Adult
Anti-Bacterial Agents - therapeutic use
Ciprofloxacin
Ciprofloxacin - therapeutic use
Colitis, Ulcerative - drug therapy
Double-Blind Method
E. coli Nissle
Escherichia coli
Female
Humans
Intestinal Mucosa - drug effects
Male
Patient Dropouts
Placebos - therapeutic use
Probiotics - therapeutic use
Remission Induction
Severity of Illness Index
Ulcerative colitis
Wound Healing
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ulcerative colitis (UC) is a chronic inflammatory bowel disease. The probiotic bacterium Escherichia coli Nissle 1917 (EcN) has been used to maintain and induce clinical remission in UC. Our aim was to test the effect of Ciprofloxacin and/or orally administered EcN as add-on to conventional therapies in patients with active UC. Our single center double-blinded randomized placebo controlled study included patients with a Colitis Activity Index (CAI) score of at least 6. Patients were randomized to Ciprofloxacin or placebo for 1week followed by EcN or placebo for 7weeks. All 4 treatments were given as add-on treatments. One hundred subjects with active UC were recruited. In the per-protocol analysis we, surprisingly, found that in the group receiving placebo/EcN fewer patients, 54%, reached remission compared to the group receiving placebo/placebo, 89%, p
ISSN:1873-9946
1876-4479
DOI:10.1016/j.crohns.2014.06.001